LPCN Projected Dividend Yield
Lipocine Inc (New) ( NASDAQ : LPCN )Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. 21 YEAR PERFORMANCE RESULTS |
LPCN Dividend History Detail LPCN Dividend News LPCN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |